Intronic SNPs of TP53 gene in chronic myeloid leukemia: Impact on drug response

Journal of Natural Science, Biology and Medicine

Volumn 3, Issue 2, 2012, Pages 182-185

  Sailaja, K ^a   Rao, V R ^b,c   Yadav, Satish ^b   Rajasekhar Reddy, R ^b   Surekha, D ^a   Nageswara Rao, D ^a   Raghunadharao, D ^d   Vishnupriya, S ^a  

^a OSMANIA UNIVERSITY   (India)

^b Anthropological Survey of India   (India)

^c UNIVERSITY OF DELHI   (India)

^d NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Association; chronic myeloid leukemia; progression; response; single nucleotide polymorphism; TP53 gene

Indexed keywords

EID: 84878780743     PISSN: 09769668     EISSN: 22297707     Source Type: Journal    
DOI: 10.4103/0976-9668.101910     Document Type: Article

References (22)

1. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, et al. P53-dependent inhibition of cyclindependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994;76:1013-23.
2. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;264:56-66.
3. Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell 1992;70:523-6.
4. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
5. Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD. P53 Mutations in human cholangiocarcinoma: A review. Liver Int 2005;25:704-16.
6. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal Structure of a p53 tumor suppressor-DNA complex: Understanding tumerogenic mutations. Science 1994;265:346-55.
7. Greenblatt MS, Bennett WP, Hollestein M, Hrris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
8. Preudhomme C, Fenaux P. The clinical significance of mutations of the p53 tumor suppressor gene in haematological. Br J Haematol 1997;98:502-11.
9. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002;21:3475-95.
10. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 1992;52:6588-93.
11. Beck Z, Kiss A, Toth FD, Szabo J, Bacsi A, Balogh E, et al. Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 2000;38:587-97.
12. Malkinson AM, Ou M. The intronic structure of cancer-related genes regulates susceptibility to cancer. Mol Carcin 1994;10:61-5.
13. Hillebrandt S, Streffer C, Reiners C, Demidchik E. Mutations in the p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Int J Radiat Biol 1996;69:39-45.
14. Peller S, Kopilova, Y, Slutzki, S, Halevy A, Kvitko K, Rotter V. A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility. DNA Cell Biol 1995;14:983-90.
15. Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, et al. A novel p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 1997;14:1541-5.
16. Hillebrandt S, Streffer C, Demidchik EP, Biko J, Reiners C. Polymorphisms in the p53 gene in thyroid tumors and blood samples of children from areas in Belarus. Muta Res 1997;381:201-7.
17. Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCAI or BRCA2 germline mutations. Br J Cancer 1999;81:179-83.
18. Lahari DK, Nuremberg JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood RFLP studies. Nucleic Acids Res 1991;19:544.
19. Berggren P, Kumar R, Steineck G, Ichiba M, Hemminki K. Ethnic variation in genotype frequencies of a p53 intron 7 polymorphism. Mutagenesis 2001;16:475-8.
20. Prosser J, Elder A, Condie A, MacFadyen I, Steel CM, Evan HJ. Mutations in p53 do not account for heritable breast cancer: A study in five affected families. Br J Cancer 1991;63:181-4.
21. Berggren P, Hemminki K, Steineck G. P53 intron 7 polymorphisms in urinary bladder cancer patients and controls. Mutagenesis 2000;15:57-60.
22. Peller S, Yona R, Kopilova Y, Prokocimer M, Goldfinger N, Uysal A, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes, Chromosomes and Cancer 1998;21:2-7.